Research Article
BibTex RIS Cite

Evaluation of the in vitro efficacy of non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing and non-producing Klebsiella spp. and Escherichia coli strains

Year 2021, Volume: 2 Issue: 2, 47 - 53, 05.06.2021
https://doi.org/10.47582/jompac.900146

Abstract

Objective: Bacteria develop resistance to many antibiotics by using different mechanisms. The resistance of bacteria secreting extended-spectrum beta-lactamases to many antibiotics limits our treatment options. In this study, we investigated the in vitro efficacies of non-beta-lactam antibiotics in Escherichia coli (E. coli) and Klebsiella spp. strains.
Material and Method: In our study, we investigated the presence of ESBL in 97 ESBL-negative (61 E. coli, 36 Klebsiella spp.) and 54 ESBL-positive (33 E. coli, 21 Klebsiella spp.) strains of nosocomial origin isolated from blood culture through a phenotypic confirmation test. We determined in vitro efficacies of aminoglycoside and quinolone group antibiotics by the agar dilution method.
Results: The susceptibility rates of ESBL-producing and non-producing strains were 81.4% -48.1% to ciprofloxacin, 85.5%-50% to levofloxacin, 81.4%-46.3% to ofloxacin and moxifloxacin, 99%-37% to gentamicin, 97.9%-57.4% to netilmicin, and 99%-96.2% to amikacin, respectively.
Conclusion: In our study, we found that all aminoglycoside and quinolone group antibiotics showed low efficacies.Amikacin had the highest in vitro activity in E. coli and Klebsiellaspp. strains.

Supporting Institution

-

Project Number

-

Thanks

-

References

  • Bush K, Bradford PA. Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020; 33: e00047-19
  • Bonomo RA. β-Lactamases: A focus on current challenges. Cold Spring Harb Perspect Med 2017; 7: a025239.
  • Bush K. Past and Present Perspectives on β-Lactamases. Antimicrob Agents Chemother 2018; 62: e01076-18.
  • Tooke CL, Hinchliffe P, Bragginton EC, et al. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol 2019; 431: 3472–500.
  • Bauvois C, Wouters J. Crystal structures of class C β-lactamases: Mechanistic implications and perspectives in drug design. In Enzyme-mediated resistance to antibiotics: Mechanisms, dissemination, and prospects for inhibition (ed. Bonomo RA, Tolmasky ME), ASM, Washington DC, 2007, pp:145–161.
  • Institute/NCCLS CaLS. Performance Standarts for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document. Clinical and Laboratory Standarts Institute, Wayne, Pennsylvania, 2005, pp:19087-1898.
  • Bush K. Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram negative infections. Crit Care 2010; 14: 224.
  • Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54: 969–76.
  • Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 273-95.
  • Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657–86.
  • Abdelaziz MO, Bonura C, Aleo A, et al. OXA-163-producing Klebsiellapneumoniae in Cairo, Egypt, in 2009 and 2010. J Clin Microbiol 2012; 50: 2489-91.
  • Lu S, Soeung V, Nguyen HAT, et al. Development and Evaluation of a Novel Protein-Based Assay for Specific Detection of KPC β-Lactamases from Klebsiella pneumoniae. mSphere. 2020; 5: e00918-19.
  • Juan C, Torrens G, Barceló IM, et al. Interplay between peptidoglycan biology and virulence in gram-negative pathogens. Microbiol Mol Biol Rev 2018; 82: e00033-18.
  • Nijssen S, Florijn A, Bonten MJ, et al. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24: 585-91.
  • Gülay Z. Gram-negatif çomaklarda antibiyotik direnci. Ankem Derg 2005; 19: 66-77.
  • Jones RN, Pfaller MA; MYSTIC Study Group (Europe). Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-12.
  • Jiang W, Yang W, Zhao X, et al. Klebsiella pneumoniae presents antimicrobial drug resistance for β-lactam through the ESBL/PBP signaling pathway. Exp Ther Med 2020; 19: 2449–56.
  • Fouhy F, Motherway MO, Fitzgerald GF, et al. In silico assigned resistance genes confer bifidobacterium with partial resistance to aminoglycosides but Not to Β-Lactams. PLoS One 2013; 8: e82653.
  • Mumcuoğlu İG, Baydur T. Escherichiae, Klebsiella ve Proteus suşlarında genişlemiş spektrumlu beta-laktamaz varlığı ve çeşitli antibiyotiklere direnç durumu. Ankem Derg 2004; 18: 9.
  • Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
  • Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583-92.
  • Heng ST, Chen SL, Wong JGX, et al. No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia. Sci Rep 2018; 8: 12785.
  • RamphalR, Amnbrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42: 164-72.
  • Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae. Clin Infect Dis 2001; 33: 1288-94.
  • Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest 2001; 119: 426-30.
  • Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
  • Essack SY. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett 2000; 190: 181-4.
  • Winokur RC, Caselles JM, and Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32: 94-103.
  • Ambrose RR. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42.
  • Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002; 14: 140-6.
  • Yu Y, Zhou W, Chen Y, et al. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae in Zhejiang Province. Chin Med J (Engl) 2002; 115: 1479-82.
  • Şahin İK, Öksüz D, Okay Ş, et al. Klinik örneklerden izole edilen Gram-negatif çomaklarda genişlemiş spektrumlu beta-laktamaz sıklığı ve antibiyotik duyarlılığı. İnffeksiyon Derg 2003; 17: 45-8.
  • Özbilge HY, İnanç F. Gram-negatif çomaklarda genişlemiş spektrumlu beta-laktamaz varlığı ve çeşitli antibiyotiklere direnç durumu. Ankem Derg 2003; 17: 13-5.
  • Zer YB, Orhan A, Çeliksöz G, Korkmaz C, et al. Hastanede yatan hastalarda izole edilen gram negative çomaklarda genişlemiş spektrumlu beta-laktamazların ve çeşitli antibiyotiklere duyarlılığın araştırılması. Anadolu Tıp Derg 2002; 4: 71-5.
  • Jones RN, Pfaller MA. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-12.
  • Domenech-Sanchez A, Pascual A, Suarez AI, et al. Activity of nine antimicrobial agents against clinical isolates of Klebsiellapneumoniae producing extended-spectrum beta-lactamases and deficient or not in porins. J Antimicrob Chemother 2000; 46: 858-9.
  • Sekowska A JG, Keyszejko C, Wojda M, et al. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics. Med Sci Monit 2002; 8: 100-4.
  • Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-9.
  • Kizirgil A, Demirdag K, Ozden M, et al. In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates. Microbiol Res 2005; 160: 135-40.
  • Rice LB. Evolution and clinical importance of extented spectrum beta lactamases. Chest 2001; 119: 391-6.
  • Kınıklı S, Cesur S, Yücel M, Ataman Hatipoğlu Ç, Dinç B. Determination of polymyxin B, minocycline, colistin and phosphomycin susceptibilities in Acinetobacter baumannii strains showing carbapenem resistant multidrug resistance phenotype. J Health Sci Med 2019; 2: 49-53.
  • Savcı Ü, Şahin M, Toprak S, Sungur M. Antimicrobial resistance pattern of Streptococcus agalactiae strains: five years evaluation of single center. J Health Sci Med 2018; 1: 25-8.

Genişlemiş spektrumlu beta-laktamaz üreten ve üretmeyen Klebsiella spp. ve Escherichia coli suşlarında beta-laktam dışı antibiyotiklerin in vitro etkinliğinin değerlendirilmesi

Year 2021, Volume: 2 Issue: 2, 47 - 53, 05.06.2021
https://doi.org/10.47582/jompac.900146

Abstract

Amaç: Bakteriler birçok antibiyotiklere farklı mekanizmaları kullanarak direnç geliştirmektedir. Genişlemiş spektrumlu beta-laktamaz (GSBL)-üreten bakterilerin pek çok antibiyotiğe karşı dirençli olmaları tedavi seçeneklerimizi kısıtlamaktadır. Bu çalışmada in vitro olarakEscherichia coli (E. coli) ve Klebsiellaspp.suşlarında beta-laktamdışıantibiyotiklerinetkinliğiniaraştırdık.
GereçveYöntem:Çalışmamızdakankültüründenizoleedilennozokomiyalkökenli97 GSBL-negatif (61E. coli, 36Klebsiellaspp.) ve 54 GSBL-pozitif (33E.coli, 21Klebsiellaspp.) suşunda GSBL varlığıfenotipikdoğrulamatestiilearaştırıldı. Aminoglikozidvekinolongrubuantibiyotiklerin in vitro etkinlikleri agar dilüsyonyöntemiilebelirlendi.
Bulgular:GSBL-üretenveüretmeyensuşlarınduyarlılıkoranlarısırasıylasiprofloksasiniçin %81,4-48,1;levofloksasiniçin %85,5-50;ofloksasinvemoksifloksasiniçin %81,4-46,3;gentamisiniçin %99-37;netilmisiniçin %97,9-57,4 veamikasiniçinde %99-96,2 olarakbulundu.
Sonuç: Çalışılmamızda E. coliveKlebsiellasppsuşlarındatümaminoglikozidvekinolongrubuantibiyotiklerinetkinliğinindüşükolduğu;amikasininenyüksek in vitro etkinliğe sahip olduğu görüldü

Project Number

-

References

  • Bush K, Bradford PA. Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020; 33: e00047-19
  • Bonomo RA. β-Lactamases: A focus on current challenges. Cold Spring Harb Perspect Med 2017; 7: a025239.
  • Bush K. Past and Present Perspectives on β-Lactamases. Antimicrob Agents Chemother 2018; 62: e01076-18.
  • Tooke CL, Hinchliffe P, Bragginton EC, et al. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol 2019; 431: 3472–500.
  • Bauvois C, Wouters J. Crystal structures of class C β-lactamases: Mechanistic implications and perspectives in drug design. In Enzyme-mediated resistance to antibiotics: Mechanisms, dissemination, and prospects for inhibition (ed. Bonomo RA, Tolmasky ME), ASM, Washington DC, 2007, pp:145–161.
  • Institute/NCCLS CaLS. Performance Standarts for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document. Clinical and Laboratory Standarts Institute, Wayne, Pennsylvania, 2005, pp:19087-1898.
  • Bush K. Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram negative infections. Crit Care 2010; 14: 224.
  • Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54: 969–76.
  • Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 273-95.
  • Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657–86.
  • Abdelaziz MO, Bonura C, Aleo A, et al. OXA-163-producing Klebsiellapneumoniae in Cairo, Egypt, in 2009 and 2010. J Clin Microbiol 2012; 50: 2489-91.
  • Lu S, Soeung V, Nguyen HAT, et al. Development and Evaluation of a Novel Protein-Based Assay for Specific Detection of KPC β-Lactamases from Klebsiella pneumoniae. mSphere. 2020; 5: e00918-19.
  • Juan C, Torrens G, Barceló IM, et al. Interplay between peptidoglycan biology and virulence in gram-negative pathogens. Microbiol Mol Biol Rev 2018; 82: e00033-18.
  • Nijssen S, Florijn A, Bonten MJ, et al. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24: 585-91.
  • Gülay Z. Gram-negatif çomaklarda antibiyotik direnci. Ankem Derg 2005; 19: 66-77.
  • Jones RN, Pfaller MA; MYSTIC Study Group (Europe). Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-12.
  • Jiang W, Yang W, Zhao X, et al. Klebsiella pneumoniae presents antimicrobial drug resistance for β-lactam through the ESBL/PBP signaling pathway. Exp Ther Med 2020; 19: 2449–56.
  • Fouhy F, Motherway MO, Fitzgerald GF, et al. In silico assigned resistance genes confer bifidobacterium with partial resistance to aminoglycosides but Not to Β-Lactams. PLoS One 2013; 8: e82653.
  • Mumcuoğlu İG, Baydur T. Escherichiae, Klebsiella ve Proteus suşlarında genişlemiş spektrumlu beta-laktamaz varlığı ve çeşitli antibiyotiklere direnç durumu. Ankem Derg 2004; 18: 9.
  • Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
  • Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583-92.
  • Heng ST, Chen SL, Wong JGX, et al. No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia. Sci Rep 2018; 8: 12785.
  • RamphalR, Amnbrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42: 164-72.
  • Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae. Clin Infect Dis 2001; 33: 1288-94.
  • Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest 2001; 119: 426-30.
  • Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
  • Essack SY. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett 2000; 190: 181-4.
  • Winokur RC, Caselles JM, and Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32: 94-103.
  • Ambrose RR. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42.
  • Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002; 14: 140-6.
  • Yu Y, Zhou W, Chen Y, et al. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae in Zhejiang Province. Chin Med J (Engl) 2002; 115: 1479-82.
  • Şahin İK, Öksüz D, Okay Ş, et al. Klinik örneklerden izole edilen Gram-negatif çomaklarda genişlemiş spektrumlu beta-laktamaz sıklığı ve antibiyotik duyarlılığı. İnffeksiyon Derg 2003; 17: 45-8.
  • Özbilge HY, İnanç F. Gram-negatif çomaklarda genişlemiş spektrumlu beta-laktamaz varlığı ve çeşitli antibiyotiklere direnç durumu. Ankem Derg 2003; 17: 13-5.
  • Zer YB, Orhan A, Çeliksöz G, Korkmaz C, et al. Hastanede yatan hastalarda izole edilen gram negative çomaklarda genişlemiş spektrumlu beta-laktamazların ve çeşitli antibiyotiklere duyarlılığın araştırılması. Anadolu Tıp Derg 2002; 4: 71-5.
  • Jones RN, Pfaller MA. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-12.
  • Domenech-Sanchez A, Pascual A, Suarez AI, et al. Activity of nine antimicrobial agents against clinical isolates of Klebsiellapneumoniae producing extended-spectrum beta-lactamases and deficient or not in porins. J Antimicrob Chemother 2000; 46: 858-9.
  • Sekowska A JG, Keyszejko C, Wojda M, et al. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics. Med Sci Monit 2002; 8: 100-4.
  • Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-9.
  • Kizirgil A, Demirdag K, Ozden M, et al. In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates. Microbiol Res 2005; 160: 135-40.
  • Rice LB. Evolution and clinical importance of extented spectrum beta lactamases. Chest 2001; 119: 391-6.
  • Kınıklı S, Cesur S, Yücel M, Ataman Hatipoğlu Ç, Dinç B. Determination of polymyxin B, minocycline, colistin and phosphomycin susceptibilities in Acinetobacter baumannii strains showing carbapenem resistant multidrug resistance phenotype. J Health Sci Med 2019; 2: 49-53.
  • Savcı Ü, Şahin M, Toprak S, Sungur M. Antimicrobial resistance pattern of Streptococcus agalactiae strains: five years evaluation of single center. J Health Sci Med 2018; 1: 25-8.
There are 42 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Research Articles [en] Araştırma Makaleleri [tr]
Authors

Göknur Yapar Toros

Funda Timurkaynak 0000-0002-1940-9186

Project Number -
Publication Date June 5, 2021
Published in Issue Year 2021 Volume: 2 Issue: 2

Cite

AMA Yapar Toros G, Timurkaynak F. Evaluation of the in vitro efficacy of non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing and non-producing Klebsiella spp. and Escherichia coli strains. J Med Palliat Care / JOMPAC / jompac. June 2021;2(2):47-53. doi:10.47582/jompac.900146

TR DİZİN ULAKBİM and International Indexes (1d)

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]



google-scholar.png


crossref.jpg

f9ab67f.png

asos-index.png


COPE.jpg

icmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.png

pn6krf5.jpg


Our journal is in TR-Dizin, DRJI (Directory of Research Journals Indexing, General Impact Factor, Google Scholar, Researchgate, CrossRef (DOI), ROAD, ASOS Index, Turk Medline Index, Eurasian Scientific Journal Index (ESJI), and Turkiye Citation Index.

EBSCO, DOAJ, OAJI and ProQuest Index are in process of evaluation. 

Journal articles are evaluated as "Double-Blind Peer Review"